Campbell, A., Silva-Pinto, A., Nnodu, O., Manwani, D., Keefe, D., Watson, J., Reshetnyak, E., Muthusamy, V., Banerjee, P., (Adisa), O. E., Nassin, M., Dei-Adomakoh, Y. (2025). A phase III, multicenter, randomized, placebo controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult sickle cell disease patients with frequent vaso-occlusive crises: The sparkle study. Blood. https://doi.org/10.1182/blood-2025-1198